Opinion|Videos|January 11, 2024
Update from KATHERINE on Adjuvant T-DM1 for Residual Invasive HER2+ Early Breast Cancer
Medical oncologists discuss the recent update from the KATHERINE trial investigating adjuvant T-DM1 (trastuzumab emtansine) following neoadjuvant chemotherapy in patients with residual invasive HER2+ early breast cancer.
Advertisement
Advertisement
Related to this article
Among patients surveyed, 92% preferred home-based treatment, while nationwide modeling projected substantial savings in oncology resources.
The FDA accepted an sNDA for gedatolisib in PIK3CA-mutant HR+/HER2– advanced breast cancer based on the phase 3 VIKTORIA-1 trial, with a PDUFA date of June 25, 2027.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
New ACS Guidelines Push for Earlier Prostate Cancer Screening
3
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
4
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
5